PulseSight Therapeutics has dosed the first subject in the Phase I trial of its first-in-class non-viral vectorised therapy, PST-611, targeting dry age-related macular degeneration (AMD) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback